Galderma’s Nemluvio Is Off And Running In PN, Heading Towards Atopic Dermatitis
The dermatology specialist updated investors on the launch of its first biologic drug, the IL-31 inhibitor Nemluvio, during its third quarter update.
The dermatology specialist updated investors on the launch of its first biologic drug, the IL-31 inhibitor Nemluvio, during its third quarter update.